Corium Joins Russell 3000® Index
June 26 2017 - 7:30AM
Corium International, Inc. (Nasdaq:CORI), a commercial-stage
biopharmaceutical company focused on the development, manufacture
and commercialization of specialty transdermal products, today
announced that it has been added to the Russell 3000® Index as part
of Russell Investments’ reconstitution of its comprehensive set of
U.S. and global equity indexes. Corium also will be included
in the Russell 2000® Index, which excludes the largest 1,000
companies in the Russell 3000 Index. These additions became
effective after the close of the U.S. Nasdaq market on June 23,
2017. Russell indexes are used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies.
“Corium’s addition to the Russell indexes is a reflection of the
important progress we have made over the past year,” said Peter D.
Staple, President and Chief Executive Officer of Corium.
“With the recent positive data in our lead Alzheimer’s program, we
anticipate that being part of the Russell indexes will help expand
the visibility of Corium as an investment opportunity for a wider
range of investors.”
Annual reconstitution of Russell's U.S. indexes captures and
ranks the 4,000 largest U.S. stocks by total market capitalization
as of the end of May.
About FTSE Russell
FTSE Russell® is a leading global index provider creating and
managing a wide range of indexes, data and analytic solutions to
meet client needs across asset classes, styles and strategies.
Covering 98% of the investable market, FTSE Russell indexes
offer a true picture of global markets, combined with the
specialist knowledge gained from developing local benchmarks around
the world.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $8.4 trillion in
assets are benchmarked against Russell’s U.S. indexes. For
over 30 years, leading asset owners, asset managers, ETF providers
and investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create investment funds, ETFs,
structured products and index-based derivatives. FTSE Russell
indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
For more information on the Russell 3000® Index and the Russell
indexes reconstitution, go to the “Russell Reconstitution” section
on the FTSE Russell website.
About Corium
Corium International, Inc. is a commercial-stage
biopharmaceutical company focused on the development, manufacture
and commercialization of specialty pharmaceutical products that
leverage the company's broad experience with advanced transdermal
and transmucosal delivery systems. Corium has multiple
proprietary programs in preclinical and clinical development,
focusing primarily on the treatment of neurological disorders, with
lead programs in Alzheimer's disease. Corium has developed
and is the sole commercial manufacturer of seven prescription drug
and consumer products with partners Mayne Pharma and Procter &
Gamble. The company has two proprietary transdermal
platforms: Corplex™ for small molecules and MicroCor®, a
biodegradable microstructure technology for small molecules and
biologics, including vaccines, peptides and proteins. In
addition to its proprietary Alzheimer’s program, the company's
late-stage pipeline includes a contraceptive patch co-developed
with Agile Therapeutics and additional transdermal products that
are being developed with other partners. For further
information, please visit www.coriumgroup.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation
Reform Act of 1995, including statements regarding our proprietary
products and product candidates. Forward-looking statements
are based on management's current expectations and projections and
are subject to risks and uncertainties, which may cause Corium's
actual results to differ materially from the statements contained
herein. Further information on potential risk factors that
could affect Corium's business and its results are detailed in
Corium's Quarterly Report on Form 10-Q for the quarter
ended March 31, 2017, filed with the Securities and
Exchange Commission (SEC) on May 12, 2017, and other reports as
filed from time to time with the SEC. Undue reliance
should not be placed on forward-looking statements, especially
guidance on future financial or operating performance, which speaks
only as of the date they are made. Corium undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
they were made or to reflect the occurrence of unanticipated
events.
Corplex™ and MicroCor® are registered trademarks of Corium
International, Inc.“FTSE®”, “Russell®”, “FTSE Russell” and other
service marks and trademarks related to the FTSE or Russell indexes
are trademarks of the London Stock Exchange Group companies.
Source: Corium
Investor and Media Contact:
SMP Communications
Susan M. Pietropaolo
susan@smpcommunications.com
(201) 923-2049
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Apr 2024 to May 2024
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From May 2023 to May 2024